Retinoic acid and sperm production in infertile men

2024-519644-33-00 · tracked via the Priya Life Science EU tracker

Sponsor

Les Hopitaux Universitaires De Strasbourg

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Not possible to specify

Decision date

09/04/2026

Enrollment target

100

Sites

France

Condition studied

oligozoospermia

Investigational medicinal product(s)

comprimés placebo à usage thérapeutique 260mgISOTRETINOINE ACNETRAIT 40 mgcapsule molle

Eligibility

Age group

18-64 years

Sex

Male

Primary endpoint

The primary evaluation criterion is sperm production measured after 20 weeks of weekly isotretinoin treatment, compared to that of men who received a placebo

Endpoint detail

Sperm motility and morphology after 20 weeks of weekly isotretinoin treatment

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-519644-33-00 on CTIS ↗ ← All trials in the EU